An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Misregulated beta-catenin responsive transcription (CRT) is crucial in cancer development, particularly colorectal carcinomas.
• Targeting CRT is a key strategy, but developing specific inhibitors that modulate nuclear beta-catenin activity without affecting cytoskeletal function remains challenging.

Purpose of the Study:

• To develop and utilize an RNAi-based screening strategy for identifying specific inhibitors of CRT.
• To validate the specificity and efficacy of identified inhibitors against nuclear beta-catenin transcriptional activity.

Main Methods:

• An RNAi-based modifier screening strategy was employed to identify CRT inhibitors.
• The specificity of identified inhibitors was assessed by their ability to antagonize nuclear beta-catenin.
• Inhibitor efficacy was tested in blocking Wnt/beta-catenin-induced genes and phenotypes in various cell lines.

Main Results:

• The screening strategy successfully identified specific CRT inhibitors.
• These inhibitors selectively target the transcriptional function of nuclear beta-catenin.
• The identified Wnt inhibitors demonstrated cytotoxicity towards colon cancer cell lines and tumor biopsy cultures with deregulated Wnt signaling.

Conclusions:

• The developed RNAi screening approach is effective for identifying specific CRT inhibitors.
• The identified inhibitors show potential as targeted therapeutics for cancers with deregulated Wnt signaling, particularly colorectal cancers.
• These findings offer a promising avenue for clinical development of novel cancer therapies.